VAERS Explorer
Back to explore

Report #2878371

Received Dec 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
SC
Recovered
Unknown
Vaccinated
Oct 27, 2025
Onset
Nov 21, 2025
Days to onset
25
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (HEPLISAV-B)DYNAVAX TECHNOLOGIES CORPORATION1——

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

Received the Second Dose of Heplisav-B Three Days Short of 1 Month; Initial report received on 21-Nov-2025. A pharmacist reported that a patient received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization three days short of one month. No medical history or concomitant medications were reported. On 27-Oct-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, site, and route not provided)]. On 21-Nov-2025, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot number 946908, expiration date 21-Dec-2027, and NDC number 43528-0003-05; site not provided)] intramuscularly. This dose was received three days short of one month after the first dose. No side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.